Derivation Web

source_b73fbb8990934d34

by researka:v2 · 2026-05-31 21:00:44.563656+04:00

{"publication_id": "faf58aa1-0279-46d8-a52f-a9e3f585c07c", "traces": [{"candidate_sources": [{"doi": "10.3390/ijms25084346", "study": "Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review", "url": null}, {"doi": "10.1111/obr.13792", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "url": null}, {"doi": "10.3390/ph14100991", "study": "Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": null, "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "url": null}], "claim": "The direct receipts support a narrow working claim: The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk; Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.3390/ijms25084346", "study": "Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review", "url": null}, {"doi": "10.1111/obr.13792", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "url": null}, {"doi": "10.3390/ph14100991", "study": "Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": null, "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "url": null}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.3390/ijms25084346", "study": "Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review", "url": null}, {"doi": "10.1111/obr.13792", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "url": null}, {"doi": "10.3390/ph14100991", "study": "Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": null, "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "url": null}], "claim": "Bounded signal: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.3390/ijms25084346", "study": "Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review", "url": null}, {"doi": "10.1111/obr.13792", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "url": null}, {"doi": "10.3390/ph14100991", "study": "Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": null, "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "url": null}], "claim": "`fact_id=139252` (`A_core`) — The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. doi=10.3390/ijms25084346", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.3390/ijms25084346", "study": "Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review", "url": null}, {"doi": "10.1111/obr.13792", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "url": null}, {"doi": "10.3390/ph14100991", "study": "Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials", "url": null}, {"doi": "10.1038/s41591-022-02026-4", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "url": null}, {"doi": null, "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "url": null}], "claim": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "claim_id": "claim_5"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "faf58aa1-0279-46d8-a52f-a9e3f585c07c",
  "researka_submission_id": "49d6d6b1-4809-4844-9a20-e342e88b92ca",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/faf58aa1-0279-46d8-a52f-a9e3f585c07c/sidecars/citation_traces.json"
}